These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 28774876)

  • 1. Flexibility and innovation in the FDA's novel regulatory approval strategies for hematologic drugs.
    Farrell AT; Goldberg KB; Pazdur R
    Blood; 2017 Sep; 130(11):1285-1289. PubMed ID: 28774876
    [No Abstract]   [Full Text] [Related]  

  • 2. Preserve the FDA's authority.
    Guharoy R
    Am J Health Syst Pharm; 1996 Nov; 53(21):2636, 2638. PubMed ID: 8913395
    [No Abstract]   [Full Text] [Related]  

  • 3. The US Food and Drug Administration's use of regular approval for cancer drugs based on single-arm studies: implications for subsequent evidence generation.
    DeLoughery EP; Prasad V
    Ann Oncol; 2018 Mar; 29(3):527-529. PubMed ID: 29346605
    [No Abstract]   [Full Text] [Related]  

  • 4. The FDA's accelerated approval process: does the pharmaceutical industry have adequate incentives for self-regulation?
    Orlando VI
    Am J Law Med; 1999; 25(4):543-68. PubMed ID: 10629734
    [No Abstract]   [Full Text] [Related]  

  • 5. They are from the government and they really are here to help you.
    Woosley RL
    J Clin Pharmacol; 2008 Feb; 48(2):142-3. PubMed ID: 18199889
    [No Abstract]   [Full Text] [Related]  

  • 6. Federal Right-to-Try Legislation - Threatening the FDA's Public Health Mission.
    Joffe S; Lynch HF
    N Engl J Med; 2018 Feb; 378(8):695-697. PubMed ID: 29320302
    [No Abstract]   [Full Text] [Related]  

  • 7. The FDA's drug review process: ensuring drugs are safe and effective.
    Meadows M
    FDA Consum; 2002; 36(4):19-24. PubMed ID: 12184298
    [No Abstract]   [Full Text] [Related]  

  • 8. Food and Drug Administration Review and Action on Over-the-Counter Time and Extent Applications. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2016 Nov; 81(226):84465-77. PubMed ID: 27906534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA's post-approval studies continue to suffer delays and setbacks.
    Willyard C
    Nat Med; 2014 Nov; 20(11):1224-5. PubMed ID: 25375913
    [No Abstract]   [Full Text] [Related]  

  • 10. Communicating with the FDA: the "third rail" of a new model for drug development.
    Stanski DR; Orloff JJ
    J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890
    [No Abstract]   [Full Text] [Related]  

  • 11. The FDA's definitions, designations, and drug approvals: too daring?
    The Lancet Haematology
    Lancet Haematol; 2018 Aug; 5(8):e321. PubMed ID: 30075830
    [No Abstract]   [Full Text] [Related]  

  • 12. Regulatory and scientific issues regarding use of foreign data in support of new drug applications in the United States: an FDA perspective.
    Khin NA; Yang P; Hung HM; Maung-U K; Chen YF; Meeker-O'Connell A; Okwesili P; Yasuda SU; Ball LK; Huang SM; O'Neill RT; Temple R
    Clin Pharmacol Ther; 2013 Aug; 94(2):230-42. PubMed ID: 23588316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advocates call for long-term extension of the FDA's rare pediatric disease priority review program: Federal voucher program considered instrumental in shortening drug review, approval period.
    Am J Med Genet A; 2017 Jan; 173(1):7-8. PubMed ID: 27991734
    [No Abstract]   [Full Text] [Related]  

  • 14. Women's health advocates dismayed at FDA's Plan B decision.
    Ready T
    Nat Med; 2005 Oct; 11(10):1016. PubMed ID: 16211017
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA's decision on Plan B: a surrogate for lack of commitment to women's health.
    Merkatz RB
    J Womens Health (Larchmt); 2005 Nov; 14(9):860. PubMed ID: 16313214
    [No Abstract]   [Full Text] [Related]  

  • 16. Reviving the FDA's Authority to Publicly Explain Why New Drug Applications Are Approved or Rejected.
    Herder M
    JAMA Intern Med; 2018 Aug; 178(8):1013-1014. PubMed ID: 29971404
    [No Abstract]   [Full Text] [Related]  

  • 17. Progress and deficiencies in the registration of clinical trials.
    Wood AJ
    N Engl J Med; 2009 Feb; 360(8):824-30. PubMed ID: 19228628
    [No Abstract]   [Full Text] [Related]  

  • 18. Totality of the evidence at work: The first U.S. biosimilar.
    Holzmann J; Balser S; Windisch J
    Expert Opin Biol Ther; 2016; 16(2):137-42. PubMed ID: 26634611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moment of reckoning.
    Wadman M
    Nature; 2007 Apr; 446(7138):844-5. PubMed ID: 17443154
    [No Abstract]   [Full Text] [Related]  

  • 20. Recent developments in health law. Administrative law v. constitutional law: the correct decision on FDA's treatment of Plan B.
    Shachar C
    J Law Med Ethics; 2009; 37(3):523-7. PubMed ID: 19723264
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.